JOHN HOPE FRANKLIN CENTER

A modified CD40 agonist antibody called 2141-V11 demonstrated remarkable efficacy in a phase 1 clinical trial, with six of 12 patients experiencing significant tumor reduction and two achieving complete remission.

NeOnc Technologies received FDA authorization to proceed with Phase IIa/IIb clinical trial of NEO212, a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer.

Baylor College of Medicine and Duke University are conducting a clinical trial combining chemotherapy and immunotherapy before and after surgery for resectable mesothelioma patients, enrolling 52 participants.

Agenus announced the launch of the BATTMAN Phase 3 trial evaluating botensilimab (BOT) and balstilimab (BAL) combination therapy in metastatic microsatellite stable colorectal cancer patients who have exhausted treatment options.

UroMems received investigational device exemption approval from the FDA and French ANSM to begin the SOPHIA2 pivotal trial of its UroActive smart implant for treating male stress urinary incontinence.

Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.

Genflow Biosciences has formalized partnerships with Belgian research center CER Groupe and Duke University spin-out Heureka Labs to accelerate its gene therapy programs targeting age-related diseases.

Invivyd's CANOPY Phase 3 trial demonstrated that PEMGARDA (pemivibart) achieved an 84% relative risk reduction in symptomatic COVID-19 compared to placebo over six months (nominal p <0.0001).

Duke University researchers demonstrated that combining enzalutamide with standard hormonal therapy extends survival by 30% in men with metastatic prostate cancer.

Duke University researchers have developed SBI-810, an experimental non-opioid painkiller that targets specific receptors in the brain and spinal cord to provide pain relief without the addictive properties of opioids.